Response to Letter to 'Serum CRP in Durvalumab-Tremelimumab-Treated HCC: Expanding the Inflammatory Narrative'.
0/5 보강
APA
Hatanaka T, Yata Y, et al. (2025). Response to Letter to 'Serum CRP in Durvalumab-Tremelimumab-Treated HCC: Expanding the Inflammatory Narrative'.. Liver international : official journal of the International Association for the Study of the Liver, 45(9), e70309. https://doi.org/10.1111/liv.70309
MLA
Hatanaka T, et al.. "Response to Letter to 'Serum CRP in Durvalumab-Tremelimumab-Treated HCC: Expanding the Inflammatory Narrative'.." Liver international : official journal of the International Association for the Study of the Liver, vol. 45, no. 9, 2025, pp. e70309.
PMID
40856360 ↗
같은 제1저자의 인용 많은 논문 (5)
- Particle Radiation Therapy With Immunotherapy for Advanced Hepatocellular Carcinoma: Emerging Evidence and Remaining Questions.
- Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis.
- Carbon-ion radiotherapy achieves outcomes equivalent to surgical resection for hepatocellular carcinoma.
- Response to Letter to 'Serum CRP in Durvalumab-Tremelimumab-Treated HCC: Expanding the Inflammatory Narrative'.
- Comparison of Surgical Resection and Radiofrequency Ablation for Early-Stage HCC Patients With Child-Pugh Class B.